Script error: No such module "TemplatePar".Expression error: Unexpected < operator.
NS-2359 (GSK-372,475) is a serotonin-norepinephrine-dopamine reuptake inhibitor. It was under development by GlaxoSmithKline (GSK) as an antidepressant, but was discontinued in 2009 when phase II clinical trials turned up disappointing results and did not support further effort by the company. NS-2359 was also in clinical trials for the treatment of ADHD, phase II having been completed in 2007. A trial exploring the effect of NS-2359 on cocaine-experienced individuals is currently ongoing.
Cite error: Invalid
parameter "group" is allowed only.
<references group="..." />
- ↑ 1.0 1.1 "NeuroSearch announces the results of Phase II Proof of Concept studies with NS2359 in depression".
- ↑ Wilens, T. E.; Klint, T.; Adler, L.; West, S.; Wesnes, K.; Graff, O.; Mikkelsen, B. (2008). "A randomized controlled trial of a novel mixed monoamine reuptake inhibitor in adults with ADHD". Behavioral and brain functions : BBF. 4: 24. doi:10.1186/1744-9081-4-24. PMC 2442604 Freely accessible. PMID 18554401.
- ↑ http://clinicaltrials.gov/ct2/show/NCT00467428
- ↑ http://clinicaltrials.gov/ct2/show/NCT00032916